Security key
98420N105
Xenon Pharmaceuticals Inc. - Common Shares (XENE)
CUSIP: 98420N105
Q3 2017 13F Holders as of 30 Sep 2017
- Security type / class
- Equity / Common Shares
- Total 13F shares
- 9,321,729
- Total 13F value
- $27,499,118
- Share change
- -603,086
- SEC-reported price per share
- $2.95
- Number of holders
- 31
- Value change
- -$1,981,003
- Number of buys
- 8
- Number of sells
- 14
- Shares outstanding
- 92,799,600
Holder snapshot
6 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q3 2017
Institutions
31
Top holders
10
XENE full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q4 2017
Previous quarter: Q2 2017
Xenon Pharmaceuticals Inc. SEC filings
Xenon Pharmaceuticals Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 98420N105
Recent filing periods:
Ownership snapshot
Top reported holders of XENE - Xenon Pharmaceuticals Inc. - Common Shares (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
BVF INC/IL
Disclosed value leader
BVF INC/IL
Comparable rows
15/15
Latest evidence
30 Jun 2017
13F
Lead comparable stake: 3.8%
Showing 1-6 of 15 holder rows.
Quick read
BVF INC/IL leads the comparable SEC ownership view at 3.8%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens BVF INC/IL's linked filing trail.
Comparable ownership
Top 5
BVF INC/IL
3.8%
Capital World Investors
1.5%
PERCEPTIVE ADVISORS LLC
0.78%
ORBIMED ADVISORS LLC
0.68%
Alyeska Investment Group, L.P.
0.48%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| BVF INC/IL |
13F
Company
|
3.8%
|
$11,084,000
3,518,830 shares
|
— | 30 Jun 2017 |
| Capital World Investors |
13F
Company
|
1.5%
|
$4,501,000
1,429,000 shares
|
— | 30 Jun 2017 |
| PERCEPTIVE ADVISORS LLC |
13F
Company
|
0.78%
|
$2,280,000
723,853 shares
|
— | 30 Jun 2017 |
| ORBIMED ADVISORS LLC |
13F
Company
|
0.68%
|
$2,000,000
634,812 shares
|
— | 30 Jun 2017 |
| Alyeska Investment Group, L.P. |
13F
Company
|
0.48%
|
$1,390,000
441,260 shares
|
— | 30 Jun 2017 |
| DAFNA Capital Management LLC |
13F
Company
|
0.41%
|
$1,190,000
377,695 shares
|
— | 30 Jun 2017 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q3 2017
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
31
Shares
9,321,729
Rows available
31
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q3 2017 vs Q2 2017 Across Filers
Q2 2017 holders
39
Q3 2017 holders
31
Holder diff
-8
| Investor | Q2 2017 Shares | Q3 2017 Shares | Share Diff | Share Chg % | Q2 2017 value | Q3 2017 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend